Author： Lin J.H. Castora F.J.
Publisher： Elsevier
ISSN： 0003-9861
Source： Archives of Biochemistry and Biophysics, Vol.324, Iss.2, 1995-12, pp. : 293-299
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The type I DNA topoisomerase isolated from bovine liver mitochondria is demonstrated here to be inhibited by camptothecin, a plant alkaloid previously shown to target the nuclear type I topoisomerase in mammalian cells. The antitumor drug reduces the ability of the mitochondrial enzyme to relax positive as well as negative supercoils although the inhibition of the former process requires more than 60-fold more drug than the latter process. A similar response is seen with the nuclear topoisomerase I. Camptothecin also stimulates the mitochondrial topoisomerase-induced cleavage of pUC19 at numerous, discrete sites. The antitumor drug 4'-(9-acridinylamino)-methanesulfon- m -anisidide, which has been shown to target the nuclear topoisomerase II, inhibited the mitochondrial type I topoisomerase relaxation activity, but this effect was found to be the result of the drug intercalating into the negatively supercoiled DNA rather than from a specific interaction with the mitochondrial enzyme. VM-26, a nonintercalating topoisomerase II poison, showed no inhibitory effect up to a concentration of 50 mu M .
Related content
Access to resources
Recommend
By Orta Manuel Lus Mateos Santiago Corts Felipe
Mutagenesis, Vol. 24, Iss. 3, 2009-05 ,pp. :
By Mosesso P.
Mutagenesis, Vol. 13, Iss. 1, 1998-01 ,pp. :
Adaptation of topoisomerase I paralogs to nuclear and mitochondrial DNA
Nucleic Acids Research, Vol. 37, Iss. 19, 2009-10 ,pp. :
By Das Benu Brata Sen Nilkantha Roy Amit Dasgupta Somdeb Bose Ganguly Agneyo Mohanta Bikash Chandra Dinda Biswanath Majumder Hemanta K.
Nucleic Acids Research, Vol. 34, Iss. 4, 2006-01 ,pp. :